TY - JOUR
T1 - Pemetrexed (Alimta®) and gemcitabine in breast cancer patients previously treated with anthracyclines and taxanes
AU - Adjei, Alex A.
PY - 2002
Y1 - 2002
N2 - Gemcitabine (2′,2′-difluorodeoxycytidine) is a pyrimidine antimetabolite with broad activity in a variety of solid tumors including breast cancer. Pemetrexed (Alimta®) is a novel, multitargeted antifolate that inhibits 3 folate-dependent enzymes, and is also broadly active in a wide variety of solid tumors. In breast cancer, pemetrexed has activity in patients previously treated with anthracyclines and taxanes, and pemetrexed demonstrates pre-clinical and clinical cytotoxic synergy with gemcitabine. This drug combination is being evaluated in a phase II study for the treatment of metastatic breast cancer patients who have previously received a taxane and an anthracycline.
AB - Gemcitabine (2′,2′-difluorodeoxycytidine) is a pyrimidine antimetabolite with broad activity in a variety of solid tumors including breast cancer. Pemetrexed (Alimta®) is a novel, multitargeted antifolate that inhibits 3 folate-dependent enzymes, and is also broadly active in a wide variety of solid tumors. In breast cancer, pemetrexed has activity in patients previously treated with anthracyclines and taxanes, and pemetrexed demonstrates pre-clinical and clinical cytotoxic synergy with gemcitabine. This drug combination is being evaluated in a phase II study for the treatment of metastatic breast cancer patients who have previously received a taxane and an anthracycline.
KW - Anthracyclines
KW - Gemcitabine
KW - Multitargeted antifolate
KW - Pemetrexed
KW - Taxanes
KW - Vitamin supplementation
UR - http://www.scopus.com/inward/record.url?scp=0036072325&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0036072325&partnerID=8YFLogxK
U2 - 10.3816/CBC.2002.s.005
DO - 10.3816/CBC.2002.s.005
M3 - Article
C2 - 12057041
AN - SCOPUS:0036072325
SN - 1526-8209
VL - 3
SP - S21-S23
JO - Clinical breast cancer
JF - Clinical breast cancer
IS - SUPPL. 1
ER -